Hemostemix (CVE:HEM) Shares Down 5.3% – What’s Next?

by · The Markets Daily

Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price dropped 5.3% during trading on Monday . The stock traded as low as C$0.09 and last traded at C$0.09. Approximately 292,378 shares were traded during mid-day trading, a decline of 4% from the average daily volume of 304,560 shares. The stock had previously closed at C$0.10.

Hemostemix Price Performance

The stock has a fifty day moving average price of C$0.09 and a 200-day moving average price of C$0.11. The company has a market cap of C$16.96 million, a PE ratio of -3.33 and a beta of 1.01. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48.

About Hemostemix

(Get Free Report)

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.

Further Reading